DK1414467T3 - Topisk behandling af mastalgi - Google Patents

Topisk behandling af mastalgi

Info

Publication number
DK1414467T3
DK1414467T3 DK01992575T DK01992575T DK1414467T3 DK 1414467 T3 DK1414467 T3 DK 1414467T3 DK 01992575 T DK01992575 T DK 01992575T DK 01992575 T DK01992575 T DK 01992575T DK 1414467 T3 DK1414467 T3 DK 1414467T3
Authority
DK
Denmark
Prior art keywords
mastalgia
topical treatment
treatment
active ingredient
topical
Prior art date
Application number
DK01992575T
Other languages
English (en)
Inventor
Alfred Schmidt
Heinrich Wieland
Original Assignee
Medical Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7661891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1414467(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical Discoveries Inc filed Critical Medical Discoveries Inc
Application granted granted Critical
Publication of DK1414467T3 publication Critical patent/DK1414467T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Massaging Devices (AREA)
DK01992575T 2000-11-02 2001-10-30 Topisk behandling af mastalgi DK1414467T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10054294A DE10054294A1 (de) 2000-11-02 2000-11-02 Topische Behandlung bei der Mastalgie

Publications (1)

Publication Number Publication Date
DK1414467T3 true DK1414467T3 (da) 2006-08-28

Family

ID=7661891

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01992575T DK1414467T3 (da) 2000-11-02 2001-10-30 Topisk behandling af mastalgi

Country Status (10)

Country Link
US (1) US20040018991A1 (da)
EP (1) EP1414467B1 (da)
AT (1) ATE324112T1 (da)
AU (1) AU2002215982A1 (da)
CY (1) CY1106319T1 (da)
DE (2) DE10054294A1 (da)
DK (1) DK1414467T3 (da)
ES (1) ES2263682T3 (da)
PT (1) PT1414467E (da)
WO (1) WO2002036129A2 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022342D0 (en) 2000-09-12 2000-10-25 Creative Peptides Sweden Ab Reduction of the electrocardiographic QT interval
US8226972B2 (en) 2001-12-20 2012-07-24 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
ATE324880T1 (de) 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1578421A4 (en) * 2003-01-02 2009-04-22 Femmepharma Holding Co Inc PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1854465A1 (en) * 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
EP1875908A1 (de) * 2006-07-05 2008-01-09 Johannes Huber Verwendung von Chrysin
WO2008019048A1 (en) * 2006-08-04 2008-02-14 Meditrina Pharmaceuticals Use of aromatase inhibitors for thining the endometrium or treating menorrhagia
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
WO2008115413A1 (en) * 2007-03-16 2008-09-25 Meditrina Pharmaceuticals, Inc. Aromatase inhibitors for the treatment of mastalgia
US20100292150A1 (en) * 2007-12-10 2010-11-18 Meditrina Pharmaceuticals, Inc. Treatment of Menorrhagia with Aromatase Inhibitor
DE102008012988A1 (de) 2008-03-07 2009-09-10 S.W. Patentverwertungs Ltd. Zusammensetzung und Verwendungen zur Beeinflussung des Haarwachstums
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
JP6091431B2 (ja) 2011-01-31 2017-03-15 ルコラス−エム．ディー．リミテッド 医薬的使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US4937250A (en) * 1988-03-07 1990-06-26 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US4935543A (en) * 1988-05-20 1990-06-19 Takeda Chemical Industries, Ltd. Physiologically active substance tan-931, its derivatives, their production and use
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
FR2677027B1 (fr) * 1991-05-27 1993-09-10 Roussel Uclaf Nouveaux produits sterouides substitues en position 6, et comportant, en position 10, un radical thioethyle, leur procede de preparation leurs intermediaires, leur application comme medicaments.
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
CA2150326A1 (en) * 1994-05-27 1995-11-28 Kimihiro Murakami Azolyl methyl phenyl derivatives having aromatase inhibitory activity
ATE197889T1 (de) * 1994-09-14 2000-12-15 Univ Sheffield Kontrolle des haarwuchses
ATE200978T1 (de) * 1996-03-29 2001-05-15 S W Patentverwertungs Ges M B KOSMETIKUM BZW. KOSMETIKZUSAMMENSETZUNG ZUR GLÄTTUNG UND STRAFFUNG DER HAUT BEI GESTÖRTEM UNTERHAUT-BINDE-FETTGEWEBE, INSBESONDERE BEI DER ßCELLULITEß
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
US5906987A (en) * 1997-03-10 1999-05-25 Schering Aktiengesellschaft And Board Of Regents Treatment of male climacteric disorders with nitric oxide synthase substrates and/or donors, in combination with androgens and/or aromatase inhibitors
EP0943333A1 (de) * 1998-03-18 1999-09-22 S.W. Patentverwertungs GmbH Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
US6086915A (en) * 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
WO2001012206A2 (de) * 1999-08-13 2001-02-22 Heinrich Wieland Soja-glycine extracten und aromatase-hemendern zur positiven beeinflussung von kollagen

Also Published As

Publication number Publication date
US20040018991A1 (en) 2004-01-29
WO2002036129A2 (de) 2002-05-10
EP1414467A2 (de) 2004-05-06
WO2002036129A3 (de) 2004-02-26
DE10054294A1 (de) 2002-05-16
ATE324112T1 (de) 2006-05-15
DE50109650D1 (de) 2006-06-01
AU2002215982A1 (en) 2002-05-15
EP1414467B1 (de) 2006-04-26
PT1414467E (pt) 2006-09-29
ES2263682T3 (es) 2006-12-16
CY1106319T1 (el) 2011-10-12

Similar Documents

Publication Publication Date Title
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DK1414467T3 (da) Topisk behandling af mastalgi
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MX2007006539A (es) Sistema para la absorcion percutanea mejorada de los agentes beneficiadores de la piel.
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
NO20052494D0 (no) Preparater inneholdende melatonin, gingko biloba og biotin.
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
DK1526839T3 (da) Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
EA200400689A1 (ru) Фармацевтические и косметические композиции, содержащие ароматические альдегиды, содержащие оксигруппу
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
NO20073575L (no) Farmasoytiske sammensetninger for behandling av cellulitt
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
ATE395064T1 (de) Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
SE0000303D0 (sv) Novel compounds
SE0203817D0 (sv) New composition
WO2003043632A3 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer